GlassScriptPhysician profile
Warren W Geisler
NPI 1902867955
$5,422.79
in general payments reported to CMS, 2019-2025
30 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $762 · 2021: $1,200 · 2022: $843 · 2023: $899 · 2024: $425 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $612.09 | 2019-2024 | Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $500.81 | 2019-2023 | |
| Abbott Laboratories | $453.57 | 2022-2025 | Freestyle Libre |
| Pfizer INC. | $424.77 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $403.72 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $399.73 | 2019-2023 | Mitigare |
| Novo Nordisk INC | $367.18 | 2019-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $346.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.96 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $259.25 | 2022-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $228.01 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $227.51 | 2019-2025 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $157.76 | 2021-2022 | |
| Amgen INC. | $116.57 | 2019-2023 | Otezla, Repatha |
| Amarin Pharma, INC. | $100.94 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $100.87 | 2020-2023 | Shingrix, Arexvy |
| Abbvie INC. | $73.14 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.03 | 2021-2022 | |
| Gilead Sciences, INC. | $55.96 | 2021-2023 | |
| Allergan, INC. | $40.70 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $28.70 | 2020 | |
| Janssen Pharmaceuticals, INC | $28.62 | 2024 | Xarelto |
| Ironwood Pharmaceuticals, INC | $24.38 | 2021 | |
| Arkray USA, INC. | $23.25 | 2023 | |
| Phathom Pharmaceuticals, INC. | $21.73 | 2024 | Voquezna |
| Redhill Biopharma INC. | $21.45 | 2020 | |
| Horizon Therapeutics Plc | $20.06 | 2019 | |
| Althera Pharmaceuticals LLC | $15.70 | 2021 | |
| Sanofi Pasteur INC. | $14.47 | 2019 | |
| Avion Pharmaceuticals | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Geisler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.